Australia Markets close in 4 hrs 53 mins

Are these the best blue chip shares to buy on the ASX 200?

James Mickleboro
best shares

If you’re interested in adding some blue chips to your portfolio then I would suggest you consider the three listed below.

Here’s why I think they are quality options for blue chip investors in 2020:

CSL Limited (ASX: CSL)

My favourite blue chip on the Australian share market is this biotherapeutics company. I continue to believe CSL would be a great buy and hold option for investors due to the quality of its operations, talented management team, and its investment in research and development. Another positive is the favourable tailwinds the company is experiencing. These include the strong demand for immunoglobulins and the increasing utilisation for secondary immunodeficiencies. Combined, I believe CSL is well-positioned for solid earnings growth over the coming years.

ResMed Inc. (ASX: RMD)

Another blue chip to consider is ResMed. As with CSL, I think the global medical device company could be a great buy and hold option. I believe ResMed has outstanding long term growth potential due to the proliferation of obstructive sleep apnoea (OSA) and its leadership position in the growing market. Interestingly, a recent presentation reveals that the company estimates only 20% of OSA sufferers have been diagnosed at this point. This should give ResMed a significant runway for growth over the next decade as more and more diagnoses are made.

SEEK Limited (ASX: SEK) 

I think this job listings giant would be a good option for investors. Although trading conditions remain tough, it is still on course to deliver strong revenue and EBITDA growth in FY 2020. At its annual general meeting this week, management advised that it expects revenue growth of 15% to 18% and EBITDA growth of 8% to 11%. Beyond FY 2020, things look even more rosy. SEEK has an aspirational revenue target of $5 billion by FY 2025. This compares to revenue of $1,537.3 million in FY 2019.

The post Are these the best blue chip shares to buy on the ASX 200? appeared first on Motley Fool Australia.

Looking for more quality blue chip ideas? Then don't miss out on these blue chip shares that were just given buy ratings.

Our Top 3 Blue Chip Shares for 2020 – NOW AVAILABLE!

You’re invited! For a limited time, The Motley Fool Australia is giving away an urgent new investment report detailing our 3 TOP BLUE CHIP SHARES to own in 2019.

So if you like trustworthy, stable, high-performing companies that pay fat fully franked dividends – we’ve got you covered!

Stock #1 is a beloved old Australian company turning its attention to high-margin businesses... and rapidly returning cash to shareholders with its hefty dividend...

While Stock #2 is an online powerhouse that’s rapidly gaining market share all around the globe... poised for years (or even decades) of tremendous growth...

Even better, Stock #3 offers a whopping 6.5% grossed-up dividend! Which beats the rates on term deposits right out of the water – and offers the potential for capital gains, too.

You can discover all three shares inside our new report right now. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a LIMITED TIME ONLY!


More reading

James Mickleboro owns shares of SEEK Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. and SEEK Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019